EICHORPublic-registry site landscape for NCT07680829, “A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia”, a Severe Hypertriglyceridemia study sponsored by Zhejiang Doer Biologics Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07680829 (registry record) |
| Study title | A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of DR10624 Added to Standard Icosapent Ethyl Therapy in Adults With Severe Hypertriglyceridemia |
| Sponsor | Zhejiang Doer Biologics Co., Ltd. |
| Condition(s) | Severe Hypertriglyceridemia |
| Phase | PHASE3 |
| Listed sites | 1 |
| Intervention(s) | DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule, Matching Placebo Subcutaneous Injection |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07680829.
Eichor generates a preliminary site-risk snapshot for NCT07680829 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Zhejiang Doer Biologics Co., Ltd.
← Eichor home · All tracked trials · Severe Hypertriglyceridemia studies · Weekly briefs
